Welcome to our dedicated page for SHL Telemed news (Ticker: SHLT), a resource for investors and traders seeking the latest updates and insights on SHL Telemed stock.
News and updates about SHL Telemedicine Ltd. (NASDAQ: SHLT) focus on its role in personal telemedicine systems and cardiac-focused remote care. The company’s announcements highlight developments in its SmartHeart® portable 12-lead ECG technology, medical call center services and telemedicine programs across Israel, the United States and Germany.
Readers of this page can follow company press releases on topics such as clinical milestones, including the TELE-ACS trial conducted at Imperial College London and other studies involving SmartHeart. SHL also reports on participation in initiatives like the U.S. Army’s Project Convergence – Capstone 4 experiment, where SmartHeart was used in demanding field conditions for urgent cardiovascular assessment.
News items frequently cover product and service expansions, such as the launch of a SmartHeart membership program in the U.S. that combines the portable ECG device with 24/7 cardiologist interpretation and telehealth visits, or the introduction of at-home Biomarker blood tests in Israel guided by SHL’s medical team. Updates on partnerships, including integration of SmartHeart into DocGo’s mobile health units and virtual visit services with BARMER in Germany, also feature prominently.
Investors and healthcare observers can also find financial and corporate communications, including annual results, regional performance highlights, research coverage summaries and notices of conference calls or shareholder meetings. This news feed provides a centralized view of SHL Telemedicine’s disclosed activities in telemedicine, cardiac diagnostics and international market development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.